GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2026)

GoodRx Holdings has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $2.3 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 77.67% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $7.1 billion (up 32.42% YoY), while the FY2025 annual figure was $1.4 billion, up 1.15% from the prior year.
• Liabilities and Shareholders Equity came in at $2.3 billion for Q2 2026 at GoodRx Holdings, up from $2.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q2 2026 to a low of $1.3 billion in Q1 2025.
• Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.6 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity retreated 20.68% in 2024 and soared 77.67% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.6 billion in 2022, then retreated by 0.99% to $1.6 billion in 2023, then retreated by 12.63% to $1.4 billion in 2024, then rose by 1.15% to $1.4 billion in 2025, then jumped by 66.87% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $2.3 billion in Q2 2026, $2.0 billion in Q1 2026, and $1.4 billion in Q4 2025.